Cannabis

What Cannabis Is

Cannabis, the genus encompassing Cannabis sativa, C. indica, and C. ruderalis, often hybridised beyond clear taxonomic distinction in commercial cultivation, is a flowering plant producing over 100 identified cannabinoid compounds, the most pharmacologically significant being delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the primary psychoactive compound. CBD is non-intoxicating and modulates THC's effects. The ratio of THC to CBD in commercial cannabis has shifted dramatically in recent decades: selective breeding for potency has produced products with much higher THC concentrations and lower CBD content than cannabis encountered in most of the twentieth century.

Cannabis is consumed by smoking, vaporising, oral ingestion (edibles), sublingual tincture, and topical application, with meaningfully different pharmacokinetic profiles across routes. Smoked and vaporised cannabis produces effects within minutes; edibles require 30–90 minutes to onset but can produce significantly more intense and longer-lasting effects than the same amount smoked, due to first-pass metabolism converting THC to 11-hydroxy-THC, a more potent compound with better CNS penetration.

Is cannabis a psychedelic?

This is a genuinely contested question. Cannabis does not fit the standard classification of “classic psychedelic”, it does not act primarily through 5-HT2A receptor agonism and its phenomenological character differs substantially from psilocybin, LSD, or mescaline. At low to moderate doses, its effects are more accurately described as sedating, anxiolytic, or mildly euphoric. However, at high doses, particularly with high-THC preparations taken orally, cannabis can produce experiences that are distinctly psychedelic in character: ego dissolution, time distortion, paranoia, visual phenomena, and a quality of expanded or altered awareness that qualifies as genuinely non-ordinary consciousness.

Cannabis has been described as an “entactogen” (at low doses, producing emotional openness and sensory enhancement), a mild anxiolytic, and, at high doses, as producing psychedelic states. Its effects are extraordinarily dose-dependent: a dose that produces mild relaxation in a regular user can produce a frightening dissociative experience in a naive user. This dose-dependence is more extreme with edibles, where onset delay leads many people to consume additional doses before the first has peaked, resulting in dramatically higher total intake than intended.

Within the psychedelic community, cannabis is often used as an adjunct to psychedelic experiences (see combining cannabis with psychedelics), and some ceremonial traditions incorporate cannabis as a sacramental substance in its own right. The relationship between cannabis and the Psygaia framework's ecological themes is interesting: cannabis has been associated with enhanced nature-relatedness and sensory receptivity in some users and contexts, though the research here is far less developed than for classic serotonergic psychedelics.

Where Cannabis Comes From

Cannabis is among the oldest domesticated plants there is. Genomic work published in 2021, comparing hundreds of genomes from across the world, points to a single domestication event in East Asia around twelve thousand years ago, most likely in what is now northwest China. Every hemp variety and every drug variety alive today descends from that event. The wild ancestral populations are essentially gone, absorbed into cultivated lineages.

What happened after domestication is a long divergence in what people were selecting for. One line was bred for fibre and seed, producing tall plants with negligible cannabinoid content. The other was bred for resin, producing the plants people smoke. Both are Cannabis sativa. The line between hemp and cannabis today is a legal threshold rather than a botanical boundary, usually set at a fraction of a percent of THC by dry weight, and a plant a hair over that line is the same species as one a hair under it.

What indica and sativa actually mean

Almost nothing, as the words are used commercially. The distinction began as an eighteenth-century taxonomic argument about whether Indian cannabis was a separate species from European cannabis. It became a shorthand in which indica means a sedating body effect and sativa means an energising cerebral one, and that shorthand has no consistent chemical basis. Analyses comparing labelled strains against their actual cannabinoid and terpene content repeatedly find that the labels do not predict the chemistry, and decades of hybridisation mean almost nothing sold today is genetically one or the other.

What does vary meaningfully is the ratio of THC to CBD, the total potency, and the terpene profile. Those are measurable and they are printed on the label in regulated markets. A strain name is marketing, and treating it as dosing information is how people end up surprised.

From plant to product

Selective breeding has pushed THC content in commercial flower far above historical levels while CBD, which moderates some of THC's effects, has been bred down. Concentrates go further still, reaching potencies that have no traditional equivalent at all. Someone comparing their experience to cannabis from thirty years ago is comparing two quite different products.

Cultivation itself carries an environmental cost that surprises people who think of cannabis as the benign option. Indoor growing under artificial light with climate control is energy-intensive enough that in some jurisdictions it accounts for a measurable share of regional electricity demand, and greenhouse or outdoor cultivation is substantially lighter. One product that is not cannabis at all also travels under its name: synthetic cannabinoids sprayed onto inert plant matter, covered in verifying what you have.

History & Cultural Roots

Cannabis has a longer and more geographically distributed history of human use than almost any other psychoactive plant. Archaeological evidence for cannabis use in shamanic contexts in Central Asia dates to at least 2500 BCE; Cannabis sativa appears in the Chinese pharmacopoeia by 2700 BCE. In South Asia, cannabis as bhang (a drink made from cannabis leaves, milk, and spices) has been used in Hindu and Sufi spiritual practice for millennia, with specific association with the god Shiva. In Sub-Saharan Africa and the Caribbean, Rastafari developed as a spiritual movement explicitly centred on cannabis sacrament. Across Indigenous cultures in the Americas, cannabis use is historically less documented than that of native plants, though it arrived through European colonisation and was rapidly integrated in many contexts.

Western prohibition of cannabis began in the early twentieth century, led in the United States by the 1937 Marihuana Tax Act and solidified under the 1970 Controlled Substances Act, and spread internationally through US-driven treaty obligations. The contemporary legalisation movement in North America, Europe, and elsewhere represents the most significant policy reversal in the century of cannabis prohibition. As with psychedelics, the science of cannabis has been suppressed and distorted by prohibition in both directions: harms both overstated (for political reasons) and understated (by industry and advocates).

How Cannabis Works

Cannabis acts primarily through the endocannabinoid system, a diffuse modulatory system present throughout the brain and body, using endogenous cannabinoid ligands (anandamide and 2-AG) to regulate neurotransmission, inflammation, pain, mood, appetite, and memory. CB1 receptors, the primary CNS target of THC, are among the most densely expressed G-protein-coupled receptors in the brain (concentrated in the cortex, hippocampus, basal ganglia, and cerebellum) and their activation produces the characteristic psychoactive effects. CB2 receptors are more peripheral, principally involved in immune regulation.

THC acts as a partial agonist at CB1 receptors, mimicking anandamide but with longer duration and stronger effect at typical doses. Its psychoactive effects arise from disruption of normal endocannabinoid signalling: alterations in sensory processing, time perception, working memory, and prefrontal executive function. CBD acts as a negative allosteric modulator at CB1 receptors, it does not activate them directly but modifies how THC activates them, attenuating some of THC's psychoactive and anxiogenic effects. This is why high-CBD preparations are generally less anxiety-provoking and less psychoactive than high-THC preparations.

The subjective effects of cannabis are among the most powerfully shaped by expectation and set of any commonly used substance. Regular users develop significant tolerance to CB1-mediated effects; naive users can experience intense psychoactive effects at doses that produce little response in experienced users.

Effects

Low to moderate doses

At typical smoked or vaporised doses in experienced users: mild euphoria; relaxation or sedation; enhanced sensory perception (music, food, and touch often become more vivid and pleasurable); altered time perception (time slows subjectively); increased sociability or introspection depending on the individual and context; and mild short-term memory impairment. The classical stereotype of the relaxed, hungry, sociable cannabis user reflects low-to-moderate dose effects in tolerance-adapted individuals.

High doses

At high doses (or at any dose in naive users, particularly via edibles) effects escalate significantly: marked paranoia; intense anxiety or panic; pronounced dissociation (feeling separated from one's body or surroundings); visual phenomena; heart rate elevation that can reach levels that feel alarming; and in some cases, experiences indistinguishable in character from an acute psychotic episode. “Greening out”, cannabis-induced nausea and vomiting, is associated with very high doses, particularly in inexperienced users. Cannabinoid hyperemesis syndrome (CHS), paradoxical recurrent vomiting in heavy long-term users, is a distinct and increasingly documented condition.

Edibles: a special case

Edible cannabis deserves special attention because the pharmacokinetic profile creates specific risks. Onset is delayed 30–90 minutes, and peak effects arrive 2–4 hours after consumption, much later than users who are accustomed to inhaled cannabis expect. Consuming additional product because “nothing is happening” at 45 minutes is the most common route to an unintended high-dose experience. 11-Hydroxy-THC, produced by hepatic metabolism of orally consumed THC, is more potent and longer-lasting than THC itself. A 10mg THC edible in a naive user can produce effects equivalent to much higher smoked doses.

Dosage and Method

Cannabis is the substance on this site where dosing goes wrong most often, and it goes wrong in a specific and predictable way. The unit that matters is milligrams of THC, and the same number of milligrams behaves like two different drugs depending on whether you inhale it or swallow it.

Inhaled

Effects begin within seconds to a couple of minutes, peak around ten to thirty minutes, and largely resolve within two to four hours. This fast feedback is what makes inhalation relatively forgiving: you find out where you are before you have committed to more. The workable method is to take one inhalation, wait fifteen minutes, and decide then. With modern flower a single inhalation delivers a few milligrams of THC, and with concentrates it can deliver many times that, which is why dabbing is a different proposition rather than a stronger version of the same one.

Oral, where the accidents happen

Swallowed THC takes thirty minutes to two hours to arrive, sometimes longer on a full stomach, peaks at two to four hours, and can last six to eight hours or well beyond. It is also chemically different by the time it reaches the brain. First-pass metabolism in the liver converts a substantial portion of THC into 11-hydroxy-THC, which is more potent and crosses into the brain more readily. An edible behaves as a longer, stronger, and less controllable experience than the same material smoked.

Two further points that catch people out. Tolerance to THC develops quickly and substantially, so a daily user's normal amount can be a genuinely frightening dose for someone who does not use, and offering an edible without saying the milligrams is not a kindness. And homemade edibles are effectively unlabelled, because the potency of the plant material and the efficiency of the infusion are both unknown, which puts a home-baked item closer to the unregulated product category than a shop-bought one.

What the Research Shows

Cannabis has a substantially larger clinical evidence base than most classic psychedelics, having been studied intensively despite (and sometimes because of) its contested legal status. Findings include:

Pain: The most consistent evidence supports cannabis for chronic pain, particularly neuropathic pain. A substantial body of randomised and observational evidence supports efficacy, and cannabis is used medically in this context across numerous legal jurisdictions.

Anxiety and PTSD: The picture is mixed and dose-dependent. Low-dose CBD and balanced THC/CBD preparations show anxiolytic effects in controlled studies. High-THC preparations can worsen anxiety and PTSD symptoms, and long-term heavy use is associated with increased rather than decreased anxiety. Observational studies from cannabis-for-PTSD programmes report symptom improvement, but methodological quality is generally limited.

Depression: No clear evidence supports cannabis as an antidepressant. Long-term heavy cannabis use is associated with increased risk of depressive episodes, particularly in individuals with genetic vulnerability. Short-term mood elevation from cannabis does not translate to therapeutic benefit for major depressive disorder.

Sleep: Cannabis reduces sleep latency and can help with short-term sleep difficulties, but long-term heavy use disrupts sleep architecture (particularly REM sleep) and is associated with reduced sleep quality after tolerance develops.

Psychosis risk: This is the area of clearest established harm. High-potency THC (above 10% concentration) is associated with higher risk of psychotic episodes in vulnerable individuals, and regular use of high-THC products approximately doubles the risk of psychotic disorder in epidemiological studies (Di Forti et al., 2019). The risk is concentrated in people with genetic vulnerability (family history of psychosis), those who begin use in adolescence, and those who use high-potency products frequently. This risk is real and should not be minimised, it represents one of the most clearly established harms in the cannabis literature.

Risks & Harms

Cannabis use disorder: Approximately 9% of people who ever use cannabis develop dependence; this rises to 17% among those who begin in adolescence and approximately 50% among daily users. Cannabis use disorder is real, involves tolerance, withdrawal (irritability, sleep disruption, appetite loss, anxiety), and craving, and represents an under-recognised public health issue as legalisation normalises heavy use.

Adolescent brain development: Regular cannabis use during adolescence, when the endocannabinoid system plays a critical role in brain development, is associated with persistent effects on executive function, memory, and mental health risk. This is among the most clearly established and most important harms in the cannabis literature. The relevant risk window extends to approximately age 25.

Respiratory harms from smoking: Combustion cannabis carries the same carcinogenic compounds as tobacco smoke and is associated with bronchitis and respiratory symptoms. Vaporisation eliminates combustion products and is meaningfully safer for the respiratory system than smoking.

Driving: Cannabis impairs reaction time, tracking ability, and decision-making and is associated with increased crash risk. The impairment window extends significantly beyond the subjective high, particularly with regular users who may feel sober while cognitively impaired.

Verifying What You Have

Cannabis is the one substance here where a large share of readers can buy a tested, labelled product from a shop, and the gap between that and the unregulated alternative is wider than most people assume.

In a regulated market

Legal product carries a label stating THC and CBD content, and it has been tested for pesticides, heavy metals, moulds, and residual solvents. That label is the single most useful harm-reduction tool available for this substance, because it converts an unknown into milligrams you can dose by. Treat it as approximately rather than exactly right. Independent checks have repeatedly found labelled THC percentages running higher than the actual content, and the incentive runs in that direction, so the label is a reasonable ceiling rather than a guarantee.

Outside one

Unregulated cannabis has no potency information, which makes oral dosing largely guesswork, and it carries three contamination risks worth naming.

• Synthetic cannabinoids. Compounds such as those sold as Spice or K2 are sprayed onto inert plant material and are not cannabis in any meaningful sense. They act far more strongly at the same receptors, with no CBD or anything else moderating them, and they have caused seizures, psychosis, and deaths. Potency varies wildly between and within batches because the spraying is uneven. You cannot identify them by sight or smell, and effects that are much stronger and stranger than expected are the usual first sign.
• Mould and microbial contamination. Poorly dried or badly stored flower can carry Aspergillus and similar organisms, which matters most for anyone immunocompromised. Visible fuzz, a musty or ammoniac smell, and material that was stored damp are all reasons to discard it.
• Pesticides and heavy metals. Cannabis takes up metals from soil readily, and unregulated cultivation has no restrictions on what gets sprayed. Neither is detectable without a laboratory.

Vape cartridges deserve their own warning

The 2019 outbreak of severe lung injury in the United States, which hospitalised thousands and killed dozens, was traced to vitamin E acetate used as a thickening agent in illicit THC vape cartridges. It was not caused by cannabis or by vaporising flower. It was caused by an additive in unregulated oil cartridges, and the incentive to cut oil with something cheap has not gone away. Unregulated cartridges are the highest-risk cannabis product available and the one where buying from a tested source matters most.

There is no useful home test for cannabis. Reagent kits do not apply, and consumer potency kits are crude. The practical answer is source rather than chemistry: buy tested product where you legally can, and where you cannot, treat potency as unknown and avoid oil cartridges from unknown suppliers entirely.

Legal Status

Cannabis is undergoing a global regulatory transformation. Canada legalised recreational cannabis nationally in 2018, the most comprehensive national legalisation framework in the world. In the United States, recreational cannabis is legal in 24 states and the District of Columbia; medical use is legal in 38 states; federal law still classifies it Schedule I, creating ongoing regulatory conflicts. Uruguay, Germany, Malta, Luxembourg, and the Netherlands (ongoing tolerance policy) have various forms of legalisation or decriminalisation in Europe. Most of Asia, Africa, and the Middle East maintain strict prohibition. Australia permits medical cannabis nationally and recreational use in the ACT. The legal position is changing rapidly and jurisdiction-specific verification is essential.

If You Are Considering This

Most readers arrive at this page already having a relationship with cannabis rather than deciding whether to start, which makes this section slightly different from its equivalents elsewhere on the site. Four things are worth deciding deliberately.

Combining cannabis with psychedelics

Cannabis is the most commonly added substance in psychedelic contexts, and the interaction is significant enough to deserve a decision rather than a habit. During the descent or afterglow of a psilocybin or LSD experience, a small amount can re-intensify effects and extend reflection, and this is how many experienced users incorporate it. Taken during the peak, or in a larger amount, it can tip a manageable experience into an overwhelming one, producing sharp increases in anxiety, paranoia, or dissociation. There are well-documented cases of people who were doing fine being pushed into acute crisis by adding cannabis.

The mechanism is partly pharmacological, since the CB1 and 5-HT2A systems interact, and partly that cannabis amplifies whatever is already present, in either direction. Timing is the variable that matters most, and a badly timed addition cannot be undone. Most harm-reduction guidance recommends leaving it out entirely for anyone inexperienced. If you are going to use it at all, decide when and how much before the day begins, and check the interaction checker for anything else in the mix.

Edibles need a rule, not an intention

The dosage section explains why. The rule that prevents nearly all of it: 2.5 mg to start, two hours minimum before anything more, and the milligrams checked on the package rather than inferred from the serving size. Apply it especially when someone else has offered you something homemade.

Frequency is the risk that creeps

Unlike classical psychedelics, cannabis lends itself to daily use, and daily use is where dependence lives. Roughly one in ten people who use cannabis develop a use disorder, and that figure rises sharply among people who start young and among daily users. Withdrawal is real, and irritability and disrupted sleep on stopping are signs of dependence rather than evidence that you needed it. If cannabis has become the thing that ends every day, that pattern is worth examining while it still feels like a choice.

Two hard lines

Regular use before roughly age 25 carries the clearest evidence of lasting harm anywhere in the cannabis literature, because the endocannabinoid system is doing developmental work during that window. And impairment behind the wheel outlasts the subjective high considerably, which regular users are worst placed to judge in themselves. Neither of these is a moral position. They are the two places where the evidence is strong enough to be stated without hedging.

Cannabis is the substance here most likely to be treated casually and most likely to reward being treated deliberately. Know the milligrams, know the frequency, and the rest of it mostly takes care of itself.

Frequently Asked Questions